Early Diagnosis Opportunity Leverage Optina's Retinal Deep Phenotyping platform and FDA Breakthrough designation for Alzheimer's to position as a pathway for early diagnosis in eye and systemic diseases, enabling cross-selling to neurology and geriatrics segments seeking early-stage dementia and memory loss screening.

Aging Care Market Target healthcare systems and aging-population programs that face strain from rising elderly care needs; offer scalable retinal imaging-based diagnostics to improve efficiency, triage, and precision medicine in memory, eye health, and cardiovascular comorbidity management.

Clinical Study Partnerships Capitalize on past and ongoing collaborations (Wagner Macula Retina Center, in-community access programs) to propose joint studies or pilot programs with hospitals and eye clinics, accelerating adoption and generating real-world evidence for reimbursement and regulatory submissions.

Investment & Funding Signals Recent funding and strategic interest from ADDF and venture groups indicate market validation; pursue conversations with potential investors and health systems about co-funding further clinical trials, registry data, and payer demonstrations to support broader market rollout.

Global Regulatory Ready With FDA Breakthrough designation and Health Canada licensing for the Optina-4C hyperspectral camera, position as a globally compliant platform ready for multi-region expansion, targeting international healthcare providers, distributors, and turnkey deployment partners.